Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: J Thorac Oncol. 2019 Jun 20;14(9):1666–1671. doi: 10.1016/j.jtho.2019.06.009

Table 2. Patients with MET amplification or METex14 mutation.

Five patients with either MET amplification or METex14 mutation are identified. MET amplification was detected by FISH in 2/3 (67%) of the patients. Next-generation sequencing detected a concurrent KRAS G12C mutation in both. Amplification in case 3 was detected by next-generation sequencing. One out of three patients that were MET amplified were also MET IHC positive by H-score. METex14 was seen in two patients and both were MET IHC positive. These results were unchanged when using IHC status by MetMab scoring criteria.

MET Amplification MET mutation by NGS Other Drivers MET IHC by H-score
Case 1 Positive by FISH (MET/CEP7 3.1) None KRAS G12C Negative
Case 2 Positive by FISH (MET/CEP7 3.3) None KRAS G12C Positive
Case 3 MET amplified by NGS (Fold 4.4) None None Negative
Case 4 None METex 14 None Positive
Case 5 None METex 14 None Positive